FDA Empower Pharmacy Warning Letter 2026: GLP-1 Compounding, Sterility & CGMP Compliance Guide

The U.S. Food and Drug Administration (FDA) has issued a new warning letter to Empower Clinic Services, LLC, doing business as Empower Pharmacy, citing violations involving compounded GLP-1 drug products and serious manufacturing and sterility concerns.

The FDA warning letter, dated September 18, 2026, follows an inspection conducted from November 3–14, 2025, at Empower Pharmacy's Houston, Texas facility. FDA stated that investigators found evidence indicating that certain compounded products did not meet the conditions required for exemptions under Section 503A of the Federal Food, Drug, and Cosmetic Act (FD&C Act). The agency also identified insanitary conditions and significant CGMP deficiencies associated with products intended to be sterile.

Among the products identified by FDA were compounded formulations of semaglutide and tirzepatide, including products that FDA determined appeared to be essentially copies of commercially available FDA-approved products.

The warning letter highlights a broader regulatory issue for compounders: compounding exemptions does not eliminate requirements relating to product quality, sterility, manufacturing controls or applicable federal law.

What Happened at Empower Pharmacy?

According to FDA, investigators reviewed Empower Pharmacy's operations and collected evidence concerning compounded products manufactured and distributed by the company.

FDA concluded that certain products did not qualify for the exemptions provided under Section 503A.

The agency specifically cited products including:

• Tirzepatide/Niacinamide
• Semaglutide/Cyanocobalamin
• Additional tirzepatide/niacinamide formulations

FDA stated that these products appeared to be essentially copies of FDA-approved semaglutide and tirzepatide products.

The agency also reviewed production volumes, prescriptions and documentation supporting claims that compounded products were sufficiently different from commercially available products for individual patients.

This resulted in multiple regulatory concerns involving:

503A eligibility → unapproved drug status → CGMP → sterility → labeling → manufacturing controls

What Is the Section 503A “Essentially a Copy” Issue?

Section 503A provides certain exemptions for human drug products compounded by qualifying pharmacists or physicians when specific statutory conditions are met.

One important condition concern compounded products that are essentially copies of commercially available drug products.

FDA explained in the warning letter that a compounded drug generally does not qualify for the relevant exemption when it is compounded regularly or in inordinate amounts as an essentially identical copy of a commercially available product.

An important exception can apply where there is a change made for an identified individual patient that produces a significant difference between the compounded product and the commercially available drug, as determined by the prescribing practitioner.

FDA stated that its inspection identified prescriptions that:

• Did not contain a prescriber determination of significant difference;
• Included purported determinations that appeared repeatedly across numerous records; and
• Were associated with substantial production volumes.

The agency said these factors raised questions about whether the individualized clinical determination required under Section 503A was being made for individual patients.

Why GLP-1 Compounding Is Under Regulatory Attention

Compounded semaglutide and tirzepatide products have received substantial FDA attention because of the widespread demand for GLP-1 medicines.

FDA has previously exercised enforcement discretion relating to certain compounded semaglutide and tirzepatide products while those drugs were on the FDA drug shortage list. According to the Empower warning letter, that enforcement discretion ended for tirzepatide injection products on March 5, 2025, and for semaglutide injection products on April 24, 2025.

FDA continues to distinguish between:

FDA-approved GLP-1 products

and

Compounded GLP-1 products

Compounded drugs are not FDA-approved products. FDA has also stated that compounded versions may present risks because FDA does not review them for safety, effectiveness and quality in the same premarket approval process used for approved drugs.

Sterility and Insanitary Conditions: A Major Concern

The Empower warning letter goes beyond the question of whether the compounded GLP-1 products qualified for 503A exemptions.

FDA investigators also identified conditions that the agency said could compromise the sterility of products intended to be sterile.

Examples included:

1. Inadequate Smoke Studies

FDA stated that Empower had not adequately performed smoke studies under dynamic conditions to demonstrate appropriate unidirectional airflow within the ISO 5 area.

For sterile drug manufacturing, airflow visualization is an important component of demonstrating appropriate control of the aseptic processing environment.

2. Deficiencies in Media Fills

FDA also found that media files were not performed under the most challenging or stressful conditions.

Media-fill simulations are used to assess whether an aseptic process can consistently operate without introducing microbial contamination.

FDA questioned documentation associated with empowers January 2026 media-fill exercise, including discrepancies in vial counts, unexplained documentation entries and transcription practices.

Key CGMP Deficiencies Identified by FDA

FDA identified several CGMP violations associated with ineligible drug products.

The warning letter cites deficiencies involving:

FDA stated that these deficiencies could cause products intended to be sterile to become contaminated or otherwise rendered injurious to health.

Why Data Integrity Matters in Sterile Drug Manufacturing

One particularly important aspect of the warning letter is FDA's concern about documentation surrounding the media-fill exercise.

FDA noted discrepancies between the summary report and underlying media-fill records.

The agency also identified records containing entries such as “N/A” without sufficient explanation and noted that some results had been transcribed onto another form because the original results were recorded on an incorrect form.

This illustrates an important regulatory principle:

Sterility assurance depends not only on the physical manufacturing process, but also on reliable, traceable and contemporaneous documentation.

For sterile manufacturing operations, companies should maintain clear evidence demonstrating:

• What was performed
• When it was performed
• Who performed it
• Which equipment was used
• What the results were
• How deviations were handled
• Why corrections or transcriptions were made
• Who reviewed and approved the records

FDA-Approved vs Compounded GLP-1 Products

The distinction is important because a compounded drug cannot simply be presented as equivalent to an FDA-approved drug without considering applicable federal requirements.

FDA has separately warned against promotional claims that suggest compounded semaglutide or tirzepatide products are FDA-approved or FDA-evaluated.

What Happens When a Compounded Product Does Not Qualify for 503A Exemptions?

FDA explained that products that do not meet the conditions of Section 503A are not eligible for exemptions from certain FD&C Act requirements.

These can include exemptions relating to:

• FDA approval
• Adequate directions for use
• CGMP requirements

Consequently, FDA stated that empowers affected products could be subject to the applicable requirements for new drugs, labeling and CGMP.

This is a critical compliance consideration for compounders.

503A eligibility must be demonstrated not assumed.

FDA's Corrective Action Concerns

FDA reviewed empowers responses to Form FDA 483.

Although FDA considered some corrective actions potentially adequate, the agency stated that it could not fully evaluate certain corrective measures because supporting documentation was incomplete.

FDA specifically raised concerns regarding:

• Finalization of a smoke-study report
• Media-fill documentation
• Discrepancies in vial counts
• Unexplained documentation entries
• Transcription of original data
• Lack of a clear audit trail
• Evidence supporting sterility assurance

FDA requested that Empower provide a written response addressing the violations and explaining corrective actions. The warning letter provides 15 working days for the response.

What Does the Warning Letter Mean for Compounding Pharmacies?

The Empower action provides several compliance lessons for pharmacies and outsourcing operations involved in sterile compounding.

1. Establish Clear 503A Eligibility

Companies should document how individual products meet the applicable statutory conditions for compounding.

2. Assess “Essentially a Copy” Risk

Products based on commercially available drugs should receive specific regulatory assessment.

3. Strengthen Prescriber Documentation

Where a significant difference is relied upon, documentation should demonstrate genuine individualized clinical judgment.

4. Validate Sterile Processes

Aseptic processing, media fills, smoke studies, environmental monitoring and cleaning processes should be appropriately designed, executed and documented.

5. Strengthen Quality Oversight

The quality unit must have appropriate systems and authority to ensure compliance with applicable specifications and CGMP requirements.

6. Maintain Data Integrity

Corrections, transcriptions and deviations must be controlled and traceable.

GLP-1 Compounding Compliance Checklist

Companies involved in compounded GLP-1 products should consider:

• Confirm applicable 503A or 503B regulatory pathway
• Review whether products are essentially copies of commercially available drugs
• Verify individual-patient prescription requirements where applicable
• Document prescriber determinations appropriately
• Review production volumes
• Evaluating sterile manufacturing controls
• Conduct appropriate smoke studies
• Validate aseptic processes
• Perform appropriate media-fill simulations
• Establish environmental monitoring programs
• Maintain equipment qualification and maintenance
• Strengthen quality unit oversight
• Review batch and production documentation
• Maintain complete data-integrity controls
• Review labeling and promotional claims
• Establish CAPA and deviation-management systems
• Monitor FDA enforcement developments

FAQs

1. Are compounded GLP-1 drugs FDA-approved?

No. FDA states that compounded drugs are not FDA-approved. Compounding may be permitted under specific statutory conditions, but that does not make the compounded product an FDA-approved drug.

2. What did FDA allege against Empower Pharmacy?

FDA stated that certain Empower products appeared to be essentially copies of FDA-approved semaglutide and tirzepatide products and that the company did not meet applicable Section 503A conditions. FDA also identified insanitary conditions and CGMP deficiencies involving sterile drug production.

3. Were the concerns limited to GLP-1 products?

The warning letter specifically discusses multiple compounded drug products, including the cited semaglutide and tirzepatide formulations. FDA's sterility and CGMP concerns relate to the firm's manufacturing operations and products intended to be sterile.

4. Why are smoking studies important?

Smoke studies or airflow visualization studies help demonstrate airflow patterns in critical aseptic processing areas. FDA identified inadequate dynamic smoke studies as one of the deficiencies at Empower.

5. What should compounders do after this FDA action?

Compounders should review their applicable statutory pathway, product eligibility, sterile-processing controls, documentation, quality systems, data integrity and FDA inspection readiness.

Conclusion

The September 2026 FDA warning letter to Empower Pharmacy demonstrates the regulatory scrutiny surrounding compounded GLP-1 products and sterile drug manufacturing.

The action highlights two interconnected compliance areas: whether compounded products qualify for applicable statutory exemptions and whether those products are manufactured under conditions that provide appropriate quality and sterility assurance.

For compounders, the regulatory expectations extend beyond formulation.

Prescription eligibility, product differentiation, manufacturing controls, aseptic processing, environmental monitoring, quality oversight and data integrity all matter.

The Empower case also demonstrates why companies should not wait for an FDA inspection to identify gaps. A proactive compliance program can help identify vulnerabilities in 503A/503B eligibility, sterile manufacturing, documentation and quality systems before they become enforcement concerns.

As FDA continues monitoring compounded GLP-1 products, companies operating in this space should maintain strong regulatory intelligence and ensure that their operations can demonstrate compliance with the requirements applicable to their compounding pathway.

How Maven Regulatory Solutions Can Help

Maven Regulatory Solutions supports pharmaceutical, compounding and healthcare organizations with regulatory strategy, quality compliance, documentation and inspection readiness.

Our support can include:

• FDA Regulatory Compliance
• 503A/503B Regulatory Assessment
• Compounded Drug Compliance Review
• CGMP Compliance Assessment
• Sterile Manufacturing Compliance
• Aseptic Process & Validation Support
• SOP & Quality Documentation Review
• Data Integrity Assessment
• CAPA & Remediation Support
• FDA Warning Letter Response Support
• Inspection Readiness
• Regulatory Intelligence & Compliance Monitoring

Maven Regulatory Solutions — Science. Compliance. Impact.